Every DEF 14A that GlucoTrack, Inc. (GCTK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow GCTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GCTK filings page.
Glucotrack, Inc. is calling a virtual special stockholders’ meeting on September 11, 2026 to approve three proposals related to significant equity issuances and meeting adjournment mechanics.
Proposal 1 seeks approval under Nasdaq Listing Rule 5635(d) for the full issuance of common stock to White Lion Capital, LLC under a three-year equity purchase facility (ELOC Purchase Agreement) of up to $50,000,000. This includes 2,505,513 commitment shares and shares underlying a commitment warrant of up to $10,000,000 in value, which together may exceed 20% of the 10,578,822 shares outstanding as of July 14, 2026. Failure to obtain approval within 60 days would trigger $50,000 liquidated damages per 30-day period.
Proposal 2 seeks approval for the full issuance of shares issuable upon conversion of senior secured convertible Bridge Notes and exercise of Bridge Warrants issued for approximately $7.95 million of gross proceeds. At the current Floor Price of $0.079824, full conversion of outstanding principal would yield about 89,096,154 shares, and full warrant exercise could add about 159,605,930 shares, both well above the 20% Nasdaq threshold. Proposal 3 would allow adjournment of the meeting to solicit additional proxies if needed.
Glucotrack, Inc. is convening a virtual 2026 annual stockholder meeting to elect six directors, hold an advisory “say-on-pay” vote on 2025 executive compensation, ratify CBIZ CPAs P.C. as independent auditor for 2026, and consider capital-structure and warrant-related actions.
Stockholders are asked to authorize one or more reverse stock splits of common stock at an aggregate ratio of up to one-for-thirty, intended to help maintain compliance with Nasdaq’s minimum bid price requirements and potentially broaden institutional and analyst interest. They will also vote on a warrant inducement framework that would permit repricing existing private-placement warrants and issuing new inducement warrants in connection with cash exercises, structured to comply with Nasdaq Listing Rule 5635(d) and support financing flexibility following Glucotrack’s business combination with Lokahi Therapeutics. The proxy also details board independence, committee responsibilities, cybersecurity oversight and director compensation.
Glucotrack, Inc. is calling a virtual special stockholder meeting on March 12, 2026 to approve several key capital and governance items. The main proposals seek approval under Nasdaq Listing Rule 5635(d) for two highly dilutive stock issuances: up to $20.0 million of common stock to Sixth Borough Capital Fund via an equity line purchase agreement, and the full issuance of common shares underlying 2,067,182 common warrants sold in a December 2025 private placement with Armistice Capital Master Fund.
On the January 28, 2026 record date, Glucotrack had 1,011,279 shares outstanding. If all pre-funded and common warrants from the private placement are exercised and held, Armistice could own about 3,100,773 shares, or roughly 77.29% of the then-outstanding common stock, significantly diluting existing holders. The proxy explains Nasdaq’s 20% issuance limits and why stockholder approval is needed to exceed them.
Management states that failure to approve the warrant-related issuance could cut off up to roughly $8 million of potential cash from warrant exercises and may jeopardize Glucotrack’s ability to fund its business, potentially forcing liquidation or bankruptcy protection. Stockholders are also asked to ratify CBIZ CPAs P.C. as auditor for 2025, following the 2025 dismissal of Grant Thornton, whose prior reports included going concern language and identified material weaknesses in internal controls. A final proposal would allow adjournment of the meeting to solicit additional proxies if needed. The Board unanimously recommends voting “FOR” all four proposals.